Brii Biosciences Limited
BRIBF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $497 | $13,891 | $22,155 | $16,225 |
| % Growth | -96.4% | -37.3% | 36.5% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $497 | $13,891 | $22,155 | $16,225 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $58,510 | $61,839 | $126,169 | $200,530 |
| G&A Expenses | $29,113 | $37,263 | $78,629 | $93,676 |
| SG&A Expenses | $29,113 | $46,179 | $111,585 | $93,715 |
| Sales & Mktg Exp. | $0 | $8,916 | $32,956 | $39 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $87,623 | $108,018 | $237,754 | $294,245 |
| Operating Income | -$87,126 | -$94,128 | -$215,599 | -$278,020 |
| % Margin | -17,548% | -677.6% | -973.1% | -1,713.5% |
| Other Income/Exp. Net | $12,702 | -$20,444 | -$67,639 | $290,476 |
| Pre-Tax Income | -$74,424 | -$114,572 | -$283,238 | $12,456 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$74,034 | -$113,814 | -$280,535 | $15,088 |
| % Margin | -14,911.1% | -819.4% | -1,266.2% | 93% |
| EPS | -0.1 | -0.16 | -0.38 | 0.021 |
| % Growth | 37.5% | 57.9% | -1,926.9% | – |
| EPS Diluted | -0.1 | -0.16 | -0.38 | 0.021 |
| Weighted Avg Shares Out | 723,556 | 730,782 | 729,716 | 728,748 |
| Weighted Avg Shares Out Dil | 723,552 | 730,779 | 729,713 | 728,712 |
| Supplemental Information | – | – | – | – |
| Interest Income | $12,617 | $18,527 | $0 | $61,400 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $561 | $561 | $2,319 | $2,816 |
| EBITDA | -$86,565 | -$93,566 | -$213,280 | -$275,204 |
| % Margin | -17,435% | -673.6% | -962.7% | -1,696.2% |